Skip to content
20-F/A

Annual Report (Foreign)

ZHONG YUAN BIO-TECHNOLOGY HOLDINGS LIMITED

0001079973-22-001290

← back to feed
Filed
Oct 5, 2022 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2022 · Mar 31, 2022 17.55M sh
Capex FY 2022 · Mar 31, 2022 $0
Capex FY 2022 · Mar 31, 2021 $5.63K
Operating Cash Flow restated FY 2022 · Mar 31, 2022 −$396.97K
Operating Cash Flow FY 2022 · Mar 31, 2021 $309.2K
Short Term Debt FY 2022 · Mar 31, 2022 $462.03K
Short Term Debt FY 2022 · Mar 31, 2021 $402.25K
Cash And Equivalents restated FY 2022 · Mar 31, 2022 $101.72K
Cash And Equivalents FY 2022 · Mar 31, 2021 $194.59K
Cash And Equivalents FY 2022 · Mar 31, 2020 $60.79K
Stockholders Equity restated FY 2022 · Mar 31, 2022 $941.4K
Stockholders Equity FY 2022 · Mar 31, 2021 $1.5M
Stockholders Equity FY 2022 · Mar 31, 2020 $1.48M
Current Liabilities FY 2022 · Mar 31, 2022 $835.57K
Current Liabilities FY 2022 · Mar 31, 2021 $761.24K
Total Liabilities FY 2022 · Mar 31, 2022 $1.91M
Total Liabilities FY 2022 · Mar 31, 2021 $1.96M
Current Assets FY 2022 · Mar 31, 2022 $2.08M
Current Assets FY 2022 · Mar 31, 2021 $2.44M
Total Assets FY 2022 · Mar 31, 2022 $2.85M
Total Assets FY 2022 · Mar 31, 2021 $3.46M
Sga Expense restated FY 2022 · Mar 31, 2022 $1.04M
Sga Expense FY 2022 · Mar 31, 2021 $574.63K
Rd Expense FY 2022 · Mar 31, 2022 $680.31K
Rd Expense FY 2022 · Mar 31, 2021 $211.04K
Net Income FY 2022 · Mar 31, 2022 −$1.13M
Net Income FY 2022 · Mar 31, 2021 −$28.02K
Operating Income restated FY 2022 · Mar 31, 2022 −$1.13M
Operating Income FY 2022 · Mar 31, 2021 −$14.6K
Gross Profit restated FY 2022 · Mar 31, 2022 $1.48M
Gross Profit FY 2022 · Mar 31, 2021 $1.35M
Cost Of Revenue restated FY 2022 · Mar 31, 2022 $846.97K
Cost Of Revenue restated FY 2022 · Mar 31, 2021 $281.96K